【摘要】 目的探讨树突状细胞诱导杀伤细胞(DC-CIK)疗法治疗慢性淋巴细胞白血病患者的疗效以及对患者免疫功能、血小板参数的影响。方法选取2015年10月至2017年10月我院收治的慢性淋巴细胞白血病患者42例,采用随机数字表法分为观察组与对照组,每组21例。对照组患者采用环磷酰胺治疗,观察组患者在对照组治疗的基础上联合DC-CIK疗法治疗。比较两组患者的疗效、免疫功能、血小板参数及不良反应发生情况。结果观察组患者的总缓解率(95.24%)显著高于对照组(66.67%),临床疗效显著优于对照组,差异有统计学意义(P<0.05)。治疗3个周期后,观察组患者TGF-β及CD4+CD25+细胞显著低于对照组,而Hsp70及Th1/Th2显著高于对照组,差异有统计学意义(P<0.01);观察组患者的PLT、PDW、MPV以及PCT水平均显著高于对照组,差异有统计学意义(P<0.05)。治疗期间,观察组患者的不良反应发生率(9.52%)显著低于对照组(42.86%),差异有统计学意义(P<0.05)。结论 DC-CIK疗法可有效改善慢性淋巴细胞白血病患者临床症状,提高免疫功能,促使血小板趋于正常,治疗安全性高,具有一定的临床应用推广价值。更多还原

【Abstract】 Objective To investigate the effect of dendritic cell induced killer cell( DC-CIK) therapy on patients with chronic lymphocytic leukemia and the effect on immune function and platelet parameters. Methods 42 patients with chronic lymphocytic leukemia admitted in our hospital from October 2015 to October 2017 were selected. They were randomly divided into the observation group and the control group,with 21 cases in each group. The control group were treated with cyclophosphamide.The observation group were treated with DC-CIK therapy on the basis of the control group. The efficacy,immune function,platelet parameters and incidence of adverse reactions were compared between the two groups. Results The total remission rate( 95. 24%)in the observation group was significantly higher than that in the control group( 66. 67%),and the clinical efficacy was significantly better than that in the control group( P < 0. 05). After 3 cycles of treatment,the TGF-beta and CD4+CD25+cells in the observation group were significantly lower than those in the control group,while the Hsp70 and Th1/Th2 were significantly higher than those in the control group( P < 0. 05). The levels of PLT,PDW,MPV and PCT in the observation group were significantly higher than those in the control group( P < 0. 01). The incidence of adverse reactions in the observation group( 9. 52%) was significantly lower than that in the control group( 42. 86%) during the treatment period,and the difference was statistically significant( P < 0. 05).Conclusion DC-CIK therapy can effectively improve the clinical symptoms of the patients with chronic lymphocytic leukemia,improve the immune function,make the platelet parameters tend to be normal,and have high safety. It has certain clinical application and promotion value.更多还原